Ability Pharma: Ability Pharma Seeks 6 Million to Advance its Pancreatic Cancer Trial

Ability Pharma has closed 2022 with a turnover of €2.3 million, which translates into an increase of 53% compared to the income of 2021. For its part, the company's assets stand at €15 million. The latest aid that the company has received corresponds to October 2022, when Ability Pharma received €2 million of non-dilutive financing from the Ministry of Science and Innovation.